Eli Lilly Q4 Earnings: Now The Magical $1 Trillion Dollar Market Cap Is In Sight
Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.
Business Insider on MSN15d
The FDA is about to make weight-loss drugs a lot harder to get
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.
FiercePharma8d
Hims & Hers tackles pharma industry drug pricing in Super Bowl ad for compounded GLP-1s
Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...
The Best Obesity Drugs Aren’t Even Here Yet
A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like Ozempic.
Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...
Bellevue Reporter22d
The Science Behind GetSimpli Oral Tirzepatide: What Makes It So Effective?
In this review, we will explore the various aspects of GetSimpli Oral Tirzepatide, including its ingredients, benefits, usage, and pricing. By the end, you will have a comprehensive understanding ...
Business Insider15d
See ya, knock-off Ozempic
When the FDA took tirzepatide off of its shortage list in December, the stock price of Hims & Hers fell amid concerns about the telehealth company's GLP-1 business. In January, Citi downgraded its ...